BI 456906 – perVial.com

Posted on August 23, 2026 by pervial

Survodutide: Mechanism of Action and Clinical Trial Evidence

3D scientific rendering of dual GLP-1 and glucagon receptor activation by peptide ligand survodutide

An evidence-based scientific review of survodutide (BI 456906), exploring its dual GLP-1 and glucagon receptor agonism, Phase 2 trial results in MASH and o

Read more Survodutide: Mechanism of Action and Clinical Trial Evidence

Posted on August 22, 2026 by pervial

Survodutide (BI 456906): Dual GLP-1/Glucagon Receptor Agonist in Metabolic and MASH Research

3D scientific illustration of Survodutide dual GLP-1 and glucagon receptor agonist interaction

Survodutide is a dual GLP-1 and glucagon receptor agonist demonstrating potent efficacy across clinical trials for obesity, metabolic dysfunction, and stea

Read more Survodutide (BI 456906): Dual GLP-1/Glucagon Receptor Agonist in Metabolic and MASH Research